Tag

Bristol Myers Squibb

All articles tagged with #bristol myers squibb

business6 days ago•10 min saved

BMS taps Anthropic to embed Claude Enterprise Across its global operations

Bristol Myers Squibb announced a strategic agreement with Anthropic to deploy Claude across its research, development, manufacturing, commercial and corporate functions, empowering more than 30,000 employees with agentic AI. The rollout centers on Claude Code for engineering and will embed AI agents into priority workflows to accelerate target identification, trial documentation and regulatory submissions, and to speed manufacturing decisions, all while maintaining enterprise governance and secure integrations. This builds on BMS’s multi-year AI investments and a multi-vendor strategy to speed medicine discovery and delivery.

via Bristol Myers Squibb|

#anthropic #bristol-myers-squibb #business

business14 days ago•0 min saved

Hengrui-BMS strike $15.2B for 13 assets

Bristol Myers Squibb and Hengrui Pharmaceutical are pursuing a deal covering 13 assets valued at up to $15.2 billion, underscoring Hengrui’s expanding global pipeline and Western pharma collaborations.

via Endpoints News|

#13-asset-deal #bristol-myers-squibb #business

biotechpharma3 months ago•2 min saved

BMS bets on a decades-old drug, Cobenfy, to tackle Alzheimer's psychosis

Bristol Myers Squibb bets that Cobenfy, a 30-year-old drug, can become the first approved treatment for psychosis in Alzheimer's disease; its fate hinges on three pivotal trials later this year after a long-ago trial showed promise but was marred by adverse effects, a rescue journey from Eli Lilly to Karuna Therapeutics before landing with BMS.

via statnews.com|

#alzheimers-disease #biotechpharma #bristol-myers-squibb

business5 months ago•2 min saved

Bristol Myers Stock Rises Amid Delays and Updates on Alzheimer’s Drug Trials

Bristol Myers Squibb's stock rose over 5% after delaying the results of a clinical trial for Cobenfy, a drug for Alzheimer's disease psychosis, due to enrollment irregularities. The delay, expected to extend the trial completion to 2026, suggests positive trends despite concerns, and the stock's movement reflects investor optimism about the potential market and ongoing development efforts.

via Investor's Business Daily|

#alzheimers-disease-psychosis #bristol-myers-squibb #business

business7 months ago•2 min saved

Bristol Myers Squibb invests $1.5B in Orbital Therapeutics to expand cell therapy portfolio

Bristol Myers Squibb is acquiring Orbital Therapeutics for $1.5 billion to expand into in vivo CAR-T cell therapies, focusing on autoimmune diseases and leveraging Orbital's RNA-based approach to produce CAR-T cells within the body, marking a significant move in the biotech and cell therapy markets.

via Fierce Biotech|

#biotech-acquisition #bristol-myers-squibb #business

business7 months ago•0 min saved

Bristol Myers Squibb Acquires Orbital Therapeutics to Expand Cell Therapy Portfolio

Bristol Myers Squibb has acquired Orbital Therapeutics for $1.5 billion to expand its involvement in cell therapies, particularly CAR-T treatments.

via Endpoints News|

#acquisition #bristol-myers-squibb #business

business7 months ago•6 min saved

Bristol Myers Squibb Expands Cell Therapy Portfolio with Orbital Therapeutics Acquisition

Bristol Myers Squibb is acquiring Orbital Therapeutics for $1.5 billion to enhance its cell therapy portfolio with next-generation RNA medicines, including the investigational CAR T-cell therapy OTX-201, aimed at autoimmune diseases, leveraging Orbital's innovative RNA platform for more accessible and effective treatments.

via Bristol Myers Squibb|

#acquisition #bristol-myers-squibb #business

healthcare8 months ago•5 min saved

Bristol Myers Squibb's Iberdomide Shows Promise in Improving MRD Negativity in Multiple Myeloma

Bristol Myers Squibb announced that their Phase 3 EXCALIBER-RRMM study showed that combining iberdomide with standard therapies significantly improved minimal residual disease negativity rates in relapsed or refractory multiple myeloma patients, with the trial continuing to evaluate other endpoints.

via Bristol Myers Squibb|

#bristol-myers-squibb #clinical-trial #healthcare

business10 months ago•6 min saved

Bristol Myers Squibb and Bain Capital Launch New Immunology Biopharma

Bristol Myers Squibb and Bain Capital have created a new independent biopharmaceutical company, NewCo, focused on developing innovative immunology therapies for autoimmune diseases, with five assets licensed from BMS and a $300 million investment led by Bain Capital, aiming to address unmet medical needs.

via Bristol Myers Squibb|

#autoimmune-diseases #bain-capital #biopharmaceutical

business10 months ago•3 min saved

Bristol Myers' Reblozyl Faces Setbacks in Phase 3 Trials for Anemia and Myelofibrosis

Bristol Myers Squibb plans to discuss FDA approval for Reblozyl in treating anemia despite a failed phase 3 trial that narrowly missed statistical significance, citing clinically meaningful benefits and future data sharing, amidst a year of clinical setbacks for the company.

via Fierce Pharma|

#anemia #bristol-myers-squibb #business

business10 months ago•2 min saved

Bristol Myers and Pfizer Offer 40% Discount on Eliquis

Bristol Myers Squibb and Pfizer will sell Eliquis directly to patients at over 40% discount, reducing the price from around $606 to $346 per month, as part of efforts to lower drug costs amid government pressure, though the new price remains higher than insurance and Medicare negotiated prices.

via CNBC|

#bristol-myers-squibb #business #discount

business11 months ago•3 min saved

Bristol to Invest Up to $11.1 Billion in BioNTech Cancer Partnership

Bristol-Myers Squibb will pay BioNTech up to $11.1 billion to license a new cancer immunotherapy, marking a significant move in the competitive oncology market aiming to expand immune-based treatments, with the deal including upfront payments, milestone payments, and shared development costs.

via Bloomberg.com|

#biontech #bristol-myers-squibb #business

business11 months ago•2 min saved

Bristol Myers Squibb and BioNTech Announce $11 Billion Cancer Drug Partnership

Bristol Myers Squibb has signed an $11 billion partnership with BioNTech to develop and commercialize BNT327, a promising cancer drug that could rival Keytruda, with potential to treat up to 3 million patients and transform cancer care. The deal includes shared clinical trial costs and milestone payments, reflecting the drug's significant potential in immunoncology.

via Financial Times|

#biontech #bnt327 #bristol-myers-squibb

business1 year ago•3 min saved

AbbVie's Schizophrenia Drug Failure Boosts Bristol Myers

AbbVie's acquisition of Cerevel Therapeutics' experimental schizophrenia drug, emraclidine, has resulted in a significant setback after the drug failed to outperform a placebo in two clinical trials. This unexpected failure led to a 12% drop in AbbVie's stock, erasing $40 billion in value, while boosting Bristol Myers Squibb's shares by 12% as their competing drug, Cobenfy, remains unchallenged. The failure raises questions about the future of muscarinic receptor-targeting antipsychotics and may impact other companies in the field.

via BioPharma Dive|

#abbvie #bristol-myers-squibb #business

business1 year ago•2 min saved

AbbVie Shares Plunge as Schizophrenia Drug Trials Disappoint, Bristol Myers Soars

AbbVie's shares plummeted over 12% after its experimental schizophrenia drug, Emraclidine, failed to meet clinical trial goals, erasing $40 billion from its market value. The drug was acquired for $8.7 billion from Cerevel Therapeutics to compete with Bristol Myers Squibb's recently approved Cobenfy. Despite the setback, AbbVie remains committed to developing treatments for psychiatric disorders, while analysts suggest the stock sell-off may be excessive.

via Financial Times|

#abbvie #bristol-myers-squibb #business